ClinicalTrials.gg

Program

taladegib

Also written as “LY2940680”, “ENV-101 (taladegib)” and “ENV-101”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Laryngeal Diseases · Neoplasms · Neoplasm Metastasis · Small Cell Lung Carcinoma, led by 2 companies.

Furthest: phase 2, since Nov 2, 201211 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly60 open or runningphase 2since Nov 2, 2012Oct 20, 2010none ahead
Endeavor Biomedicines52 open or runningphase 2since Jun 29, 2021Jun 29, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 20, 2010First study: phase 1 study in NeoplasmsNew to Eli LillyEli Lilly · NCT01226485 · 84 enrolled · United States
  2. Sep 4, 20122 phase 1 studiesEli Lilly · NCT01681186, NCT01697514
  3. Nov 2, 2012Phase 2 study in Small Cell Lung CarcinomaEli Lilly · NCT01722292 · 26 enrolled · United States, United Kingdom
  4. Dec 7, 2012Phase 1 study in Healthy VolunteersEli Lilly · NCT01746745 · 6 enrolled · United States
  5. Aug 5, 2013Phase 1 study in Neoplasm MetastasisEli Lilly · NCT01919398 · 19 enrolled · Japan
  6. Jun 29, 2021Endeavor Biomedicines's first study: phase 2 study in Idiopathic Pulmonary FibrosisNew to Endeavor BiomedicinesEndeavor Biomedicines · NCT04968574 · 41 enrolled · Australia, Canada, Korea, Republic of and more
  7. Dec 14, 2021Phase 2 study in Laryngeal DiseasesEndeavor Biomedicines · NCT05199584 · 20 enrolled · United States
  8. Apr 5, 2023Phase 1 study in Idiopathic Pulmonary FibrosisEndeavor Biomedicines · NCT05817240 · 21 enrolled · Australia
  9. May 15, 2024Phase 2 study in Idiopathic Pulmonary FibrosisEndeavor Biomedicines · NCT06422884 · 213 enrolled · Argentina, Australia, Austria and more
  10. Mar 2, 2026Phase 1 study in Idiopathic Pulmonary FibrosisEndeavor Biomedicines · NCT07454291 · 57 planned · Australia

TargetBeta

SMO →read by rule
“Smoothened homolog antagonist”ChEMBL 37, by rule

Other programs on SMO

ProgramCompanyFurthest phaseStudies
sonidegibruleNovartisphase 416

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07454291Idiopathic Pulmonary Fibrosis · Australia1RecruitingEndeavor BiomedicinesOct 202657
NCT06422884Idiopathic Pulmonary Fibrosis · Argentina, Australia, Austria and more2Active, not recruitingEndeavor BiomedicinesOct 2026213
NCT05817240Idiopathic Pulmonary Fibrosis · Australia1CompletedEndeavor BiomedicinesJun 11, 202321
NCT05199584Laryngeal Diseases · United States2CompletedEndeavor BiomedicinesFeb 20, 202420
NCT04968574Idiopathic Pulmonary Fibrosis · Australia, Canada, Korea, Republic of and more2CompletedEndeavor BiomedicinesNov 30, 202341
NCT01919398Neoplasm Metastasis · Japan1CompletedEli LillyMay 201619
NCT01746745Healthy Volunteers · United States1CompletedEli LillyMar 20136
NCT01722292Small Cell Lung Carcinoma · United States, United Kingdom2TerminatedEli LillyFeb 201526
NCT01697514Medulloblastoma · United States1WithdrawnEli LillyJul 20160
NCT01681186Healthy Participants · United States1CompletedEli LillyDec 201230
NCT01226485Neoplasms · United States1CompletedEli LillyJan 201584

How it is read

Names in the registry

  • “LY2940680”, 4 entries
  • “taladegib”, 3 entries
  • “ENV-101 (taladegib)”, 1 entry
  • “ENV-101”, 1 entry
  • “LY2940680 Capsule(s) (Reference)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
taladegib (Eli Lilly): development program | ClinicalTrials.gg